Lifestyle overhaul may cut dementia risk in latin america
NCT ID NCT06492967
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a structured lifestyle program—including diet, exercise, and cognitive training—can help prevent cognitive decline in older adults at risk for dementia. Over 1,000 participants aged 60-77 from 12 Latin American countries took part. The goal was to see if such a program is feasible and could eventually reduce dementia rates.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- lifestyle intervention (diet, exercise, cognitive training, and cardiometabolic risk management)
- What this could lead to
- If successful, this could show that lifestyle changes can prevent or delay dementia in high-risk older adults, influencing public health policies.
- What could go wrong
- This is a feasibility study, not a large-scale trial. It measures recruitment and adherence, not whether the intervention actually prevents dementia. Results may not apply to other populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
1,065 people
The number who actually took part.
- Started
-
Oct 2021
- Finished
-
Nov 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
60 to 77 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria * Age: 60-77 years. * Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) Risk Score \> 6. * Mini-Mental State Examination (MMSE) z score between 0 and -1.5 OR * CERAD Word List Learning Task (10 word x 3 repetitions) \< 0 z score OR * CERAD (delayed word list recall) \< z score \< 0 Exclusion Criteria * MMSE \< 20 * Dementia * Any medical condition that affects the participant's safety. * Severe osteoarticular problems that preclude the implementation of the physical activity intervention outlined in the protocol, such as, for example: osteoarthrosis of the knee(s), coxofemoral, or other. * Significant neurological disease, including dementia, cognitive impairment, Parkinson's disease, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis or history of significant head injury with persistent neurological sequelae or structural brain abnormalities, major depressive disorder within the last 2 months, history of bipolar disorder or schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders V (DSM V) criteria. * Severe cardiovascular disease, including heart failure, clinically significant aortic stenosis, history of uncontrolled acute myocardial infarction (AMI) or angina and Cardiac rhythm disorders: g3 conduction block, uncontrolled arrhythmia, alterations in Q wave, S waver and T wave segment or QT segment and auricular fibrillation (AF) of less than one year of evolution, venous thrombosis or pulmonary thromboembolism (PTE) of less than 6 months of evolution and any pathology that in clinical judgment compromises the intervention of physical activity. * Body Mass Index \>40 * Cerebral vascular disease in the last 2 years. * Insulin-dependent diabetes mellitus. * Pulmonary disease requiring oxygen and/or steroids. * Renal disease defined as increased renal glomerular filtration rate \<60ml/min/1.73mt2 or albumin excretion rate (AER) \> 30mg/24 hrs. * Clinically significant laboratory abnormalities as judged by the investigator. * History within the last 2 years of treatment for primary or recurrent malignant disease. * History of hip fracture, knee replacement, or spinal surgery within the last 6 months. * Being in cardiopulmonary rehabilitation. * History of bariatric surgery. * Cardiac surgery in the last year. * Severe sensory loss or loss of communication skills. * No schooling. * Use of psychoactive medications within the past 3 months, including tricyclic antidepressants, antipsychotics, psychotropic mood-stabilizing agents (e.g., lithium salts), psychostimulants, opioid analgesics, antiparkinsonian medications, anticonvulsant medications (except gabapentin and pregabalin for non-convulsant indications), systemic corticosteroids, or medications with significant central anticholinergic activity; in the absence of major depression, stable doses of selective serotonin reuptake inhibitors or serotonin and norepinephrine reuptake inhibitors are permitted. * Active participation in another intervention study. * History of alcoholism or substance abuse in the last 2 years, according to DSM V criteria.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Antioquia University
Antioquia, Colombia
-
Centro Neurológico Mente Activa
La Paz, Bolivia
-
Clínica de la Memoria - Hospital Británico
Montevideo, Uruguay
-
Fleni
Ciudad Autonoma de Buenos Aire, Argentina
-
Hospital Clínica Bíblica
San José, Costa Rica
-
Hospital Clínico Universidad de Chile
Santiago, Chile
-
Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez
Mexico City, Mexico
-
Instituto Peruano de Neurociencas
Lima, Peru
-
Neuromedicenter - Cognitive Disorders Unit
Quito, Ecuador
-
Universidad Nacional Pedro Henriquez Urena (UNPHU)
Santo Domingo, Dominican Republic
-
Universidad de Puerto Rico
San Juan, Puerto Rico
-
Universidade Federal de Minas Gerais
Belo Horizonte, Minas Gerais, Brazil
-
University of Sao Paulo School of Medicine
São Paulo, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a massive data registry crack the code of Parkinson's and related brain diseases?
- Can a gentle electric current calm the mind in Alzheimer's?
- Alzheimer's vaccine aims to clear amyloid before memory fades
- Blood, eye, and brain scans team up to spot Alzheimer's earlier
- Can a home device slow Alzheimer's? pilot study tests pulsed electromagnetic therapy
- Eye scans as a window to the body: study probes retinal imaging across diseases